Outcomes after DIscontinuing Tumor Necrosis Factor Inhibitor (TNFi) in Rheumatoid Arthritis: 2 Years of 'Post-TNFi' after the 5-year Extension study of Golimumab in Korea
배상철
제목
Outcomes after DIscontinuing Tumor Necrosis Factor Inhibitor (TNFi) in Rheumatoid Arthritis: 2 Years of 'Post-TNFi' after the 5-year Extension study of Golimumab in Korea